首页> 外文期刊>Journal of clinical laboratory analysis. >Detection of Anti-Aquaporin-4 Antibodies in Neuromyelitis Optica: Comparison of Tissue-Based and Cell-Based Indirect Immunofluorescence Assays and ELISA
【24h】

Detection of Anti-Aquaporin-4 Antibodies in Neuromyelitis Optica: Comparison of Tissue-Based and Cell-Based Indirect Immunofluorescence Assays and ELISA

机译:视神经脊髓炎中抗Aquaporin-4抗体的检测:基于组织和基于细胞的间接免疫荧光测定法和ELISA的比较

获取原文
获取原文并翻译 | 示例
           

摘要

NMO-IgGagainst aquaporin-4 (AQP4) is a specific marker for neuromyelitis optica (NMO). We evaluated the performance of different NMO-IgG detecting methods. In 124 sera (from 54 with NMO spectrum disorders including nine with NMO, ten with multiple sclerosis including two with OSMS, and 60 with other neurological diseases), NMO-IgG was measured with tissue-based indirect immunofluorescence (IIF-tissue) using mouse cerebellum, cell-based IIF (IIF-AQP4) using transfected HEK293 cells which express human AQP4, and AQP4 autoantibody detecting enzyme linked immunosorbent assay (ELISA-AQP4). The sensitivities and specificities of three assays were 44.4-55.6% and 87.0-92.2% for detecting NMO, and 11.1-20.4% and 95.7-97.1% for detecting NMO spectrum disorders. Although there was no significant difference, the patients with NMO or NMO spectrum disorders showed higher rates of seropositivity in the ELISA-AQP4 vs. IIF assays. Out of the 19 sera with NMO-IgG, in at least one test, only six (31.6%) were found to be positive by all three assays. Among the three methods, the ranges of co-negativities, co-positivities, and agreement were 77.4-97.4%, 42.9-75.0%, and 91.1-95.2% (kappa 0.475-0.641), respectively. In patients who had positive ELISA-AQP4 results, IIF-AQP4 positivity was associated with NMO (P = 0.01). In summary, we observed an increased prevalence of NMO-IgG in patients with NMO and NMO spectrum disorders. ELISA-AQP4 may be more sensitive and specific when confirmed by IIF-AQP4.
机译:NMO-IgG对抗水通道蛋白4(AQP4)是视神经脊髓炎(NMO)的特异性标记。我们评估了不同的NMO-IgG检测方法的性能。在124份血清中(从54例NMO频谱疾病中,包括9例NMO,10例多发性硬化症(包括2例OSMS和60例其他神经系统疾病)),使用小鼠使用基于组织的间接免疫荧光法(IIF-组织)测量了NMO-IgG小脑,基于细胞的IIF(IIF-AQP4)(使用表达人AQP4的转染的HEK293细胞)和AQP4自身抗体检测酶联免疫吸附测定(ELISA-AQP4)。三种测定对NMO的敏感性和特异性分别为44.4-55.6%和87.0-92.2%,对NMO光谱异常的敏感性为11.1-20.4%和95.7-97.1%。尽管没有显着差异,但NMO或NMO频谱异常患者的ELISA-AQP4血清阳性率高于IIF分析。在至少一项测试中,在含有NMO-IgG的19份血清中,通过全部三种测定法仅发现6份(31.6%)为阳性。在这三种方法中,共阴性,共阳性和一致性的范围分别为77.4-97.4%,42.9-75.0%和91.1-95.2%(kappa为0.475-0.641)。在ELISA-AQP4结果呈阳性的患者中,IIF-AQP4阳性与NMO相关(P = 0.01)。总之,我们观察到NMO和NMO谱系障碍患者中NMO-IgG的患病率增加。经IIF-AQP4确认后,ELISA-AQP4可能更灵敏和特异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号